Yuping Sun

机构：Guangdong University of Technology · ORCID：0000-0003-3010-329X

发表论文 96 篇 · 总被引 1655 次 · h-index 21

代表论文

• Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study (2025 · The Lancet Oncology · 被引 50)
• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 21)
• Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate. (2024 · Journal of Clinical Oncology · 被引 10)
• Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study. (2024 · Journal of Clinical Oncology · 被引 9)
• 357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02 (2025 · Journal of Thoracic Oncology · 被引 7)